Date: 2015-02-04
Type of information: Financing round
Company: Capricor Therapeutics (USA - CA)
Investors: Broadfin Capital (USA - NY) Sabby Capital (USA - NJ) CureDuchenne Ventures (USA - CA)
Amount: $ 7 million
Funding type: financing round
Planned used: The net proceeds from the financing will be used primarily for working capital, including planned clinical trials, and general corporate purposes. These funds along with a recently announced financing in early January adds approximately $17.0 million in cash to the company balance sheet. They will support Capricor\'s clinical programs with cardiosphere-derived cells (CDCs) and cenderitide.
Others: * On February 4, 2015, Capricor Therapeutics, a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, has signed definitive agreements for the sale of approximately $7.0 million of the Company\'s common stock to select investors at a price of $4.25 per share. The closing of the offering is expected to take place on or about February 9, 2015, subject to the satisfaction of customary closing conditions. The common stock financing includes participation from Broadfin Capital, LLC, Sabby Capital, LLC and CureDuchenne Ventures, LLC. H.C. Wainwright & Co., LLC acted as exclusive placement agent in connection with the offering.
Therapeutic area: Cardiovascular diseases
